No. of individuals | 22 |
Mean age (years) (range) | 42.6 (20–81) |
Females | 95% |
Disease manifestations | |
Nephritis | 23% |
Vasculitis | 0% |
Arthritis | 27% |
Rash | 18% |
Alopecia | 0% |
Myositis | 0% |
Mucosal ulcers | 0% |
Serositis | 5% |
Leucopenia | 9% |
Thrombocytopenia | 14% |
Visual disturbance | 0% |
Fever | 14% |
Mean SLEDAI (range) | 6 (0–22) |
dsDNA antibody positive | 45% |
Rheumafactor positive | |
IgA | 23% |
IgM | 5% |
Low C3 or C4 level | 50% |
Mean C-reactive protein (mg/L) (range) | 4.8 (1–22) |
Medication: | |
Prednisolone (median dose, mg) | 55% (3.4) |
Azathioprine (median dose, mg) | 23% (0) |
Mycophenolate mofetil (median dose, mg) | 18% (0) |
Methotrexate (median dose, mg) | 9% (0) |
Hydroxychloroquine (median dose, mg) | 55% (200) |
Anticoagulant | 32% |
Antihypertension | 23% |
Characteristics of healthy controls | |
No. of individuals | 22 |
Mean age (years) (range) | 38.1 (25–59) |
Females | 91% |
dsDNA, double-stranded DNA; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.